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Abstract. – The world will never be the 
same after the current COVID-19 pandemic. 
We may have to live with the coronavirus for 
a long time. The severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) pandem-
ic has resulted in a major burden on the glob-
al health system and economy. This report de-
scribes the current COVID-19 landscape and 
its socioeconomic implications. Despite the 
concerns for second waves of infection, grad-
ual lifting of lockdown restrictions has oc-
curred worldwide to relieve economic pres-
sures and likely contributes towards possibly 
surging of outbreak although region wise vari-
ation exists due to several other biological fac-
tors, such as testing capacity and basic health-
care facilities among susceptible population 
within that region. Different prediction models 
have been put forth to forecast the spread of 
the current outbreak. However, it is challeng-
ing to perceive the precise changes happening 
in the real world as every time dynamics differ 
same as other epidemics cannot possibly be 
exactly superimposed to COVID-19. Current-
ly, to decrypt the conundrum for effective anti-
viral drug against SARS-CoV-2 is in full swing. 
Due to high rate of mortality and it expeditious-
ly spread is it decisive to understand the bio-
logical properties, clinical characteristics, ep-
idemiology, evolution, pathogenesis for vac-
cine development and pathogenicity studies 
against the viral curb. Instant diagnostic and 
adequate therapeutics serve as a major inter-
vention for the management of pandemic con-
tainment. Our study aims to analyze the impact 
of current measures and to suggest appro-
priate administrative strategic planning rather 
than to make somewhat authentic prediction in 
relation to the current scenario. Our predictive 
analysis study should be helpful against pre-
vention, cure and control of the current out-
break of COVID-19 till the availability of cure 
or vaccine.
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Introduction
As potentially lethal pathogens to humans, 
viruses have caused several pandemics through-
out history. On December 19, 2019, a novel 
virus called the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) emerged, 
which causes the Coronavirus disease 2019 
(COVID-19). The infectious disease started in 
patients who presented with severe pneumonia of 
unknown origin in Wuhan City, Hubei Province 
of China, the seventh largest city in China with 
11 million residents. The spread of COVID-19 
has progressed rapidly, and the World Health 
Organization (WHO) declared it a pandemic on 
March 11, 2020 due to the appearance of 118,000 
cases over 110 countries1-3. On January 10, 2020, 
genome sequencing classified the virus as part of 
the Betacoronavirus genus, confirming that the 
outbreak was due to a novel coronavirus. The 
primary source of transmission of this outbreak 
outside of Wuhan was due to infected air travel-
ers, and Thailand reported the first case outside 
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of China on January 13, 2020. Within China, new 
cases were reported outside Wuhan from Guang-
dong and Beijing on January 193,4. 
COVID-19 Global Effects
So far COVID-19 has spread over 213 countries 
and worldwide, the number of cases of coronavi-
rus have reached more than 38 million, with more 
than one million deaths; the number of recovery 
cases has reached over 25 million till October, 
2020. Global distribution of COVID-19 has been 
depicted in Figure 1. According to WHO statistics, 
at the time of this manuscript’s preparation, the 
countries with the highest incidence of COVID-19 
is the United States (US) (the first case was re-
ported on Jan 23, 2020)5,6 followed by Brazil (Feb 
27, 2020), Russia (Feb 1, 2020), United Kingdom 
(Feb 1, 2020), Spain (Feb 1, 2020), India (Jan 30, 
2020), Italy (Jan 31, 2020), France (Jan 24, 2020), 
Germany (Jan 28, 2020), Turkey (March 12, 2020), 
and Iran (Feb 19, 2020)7.
SARS-COV-2 in Depth
SARS-CoV-2 is similar to Severe Acute Re-
spiratory Syndrome coronavirus (SARS-CoV) 
virus in terms of its pathogenicity8,9. However, a 
genetic recombination event in the RBD region 
at the S protein of SARS-CoV-2 conferred higher 
infectivity compared to SARS-CoV10. Coronavi-
rus belongs to the Coronaviridae family in the 
Nidovirales order. The name “corona” originates 
from its crown-like glycoprotein spikes on the 
outer surface (envelope) of the virus. The size 
of coronavirus ranges from 65 to 125 nm in di-
ameter. The subgroups of coronaviruses family 
are alpha (α), beta (β), gamma (γ) and delta (δ) 
coronavirus10. The RNA genome of SARS-CoV2 
is single-stranded consist of 29,891 nucleotides, 
which encode 9,860 amino acids. The exact ori-
gin is still not fully understood, but 89% genomic 
similarity with bat SARS suggests that SARS-
CoV-2 may have evolved from a strain present 
in that animal. Mutations may have caused the 
spread of SARS-CoV 2 into humans11. 
The Orthocoronavirinae subfamily of Coro-
naviridae (order Nidovirales) is further classi-
fied into four CoVs genera: Alphacoronavirus 
(alpha-CoV), Betacoronavirus (beta-CoV), Del-
tacoronavirus (delta-CoV), and Gammacorona-
virus (gamma-CoV). Five sub-genera exist within 
the beta CoV genus. Genomic analyses reveal 
that bats and rodents are likely the main source 
of alpha CoVs and betaCoVs. On the other hand, 
deltaCoVs and gammaCoVs likely originate from 
avian species12. Coronaviruses are positive, sin-
gle-stranded RNA viruses, and to date, seven 
Figure 1. Virus Enveloped the Whole World. The global distribution and relative prevalence of COVID-19 are illustrated as 
the percentage of total confirmed cases. As the numbers for COVID-19 cases are changing rapidly, this chart only provides an 
approximation of the current scenario on June 7, 2020 from the John Hopkins Corona Resource Centre. Cases predominate in 
the United States and Europe.
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human coronaviruses (HCoVs) have been identi-
fied. SARS-CoV-2 falls within the Betacorona-
virus genera2,13. Other reported human CoVs are 
SARS-CoV and MERS-CoV.
Clinical Manifestation
Members of the seven previously reported 
HCoVs are capable of causing enteric, respirato-
ry, neurological, and hepatic diseases. It has been 
projected that healthy carriers of any CoV com-
prise approximately 2% of the global population, 
while respiratory infections are found in 5% to 
10% of the population. Four mostly present with 
cold symptoms; however, SARS-CoV, SARS-
CoV-2, and Middle East respiratory syndrome 
coronavirus (MERS-CoV) are more common-
ly linked to fatal illness12,14-19. The outbreak of 
COVID-19 began in Wuhan City, where several 
pneumonia patients were reported and found to 
be associated with the Huanan seafood and ani-
mal wholesale market20,21. The human to human 
transmission is considered as a major route of 
viral transmission22,23. The presence of SARS-
CoV-2 in the stool of COVID-19 patients and 
in the sewage water of Chinese hospitals where 
SARS patients have been treated also suggest the 
possibility of oral-fecal transmission24-27. 
The common symptoms associated with 
COVID-19 patients feel rigor, sore throat, high 
fever, shortness of breath, headache, nausea, vom-
iting, dry cough and diarrhea28,29. In elderly and 
immunity patients, severe lower respiratory tract 
infections have been reported. SARS-CoV-2 can 
be overlooked or misdiagnosed due to an incuba-
tion period of 2-14 days and similarity of present-
ing symptoms with the common cold. These chal-
lenges result, in part, in increased transmission 
and outbreak among people15-17. Only 2-10% of 
COVID-19 patients had gastrointestinal symptoms 
mainly vomiting, diarrhea, and abdominal pain. 
The study conducted on 99 confirmed SARS-
CoV-2 patients of Wuhan Jinyintan Hospital, Wu-
han, China, had symptoms of fever, shortness of 
breath, cough, muscle ache, fatigue, headache, 
sore throat, chest pain, diarrhea, nausea and vom-
iting30,31. SARS-CoV-2 also infects hematological, 
digestive and the urinary system thus virus can be 
observed in urine, stool and blood samples.
Viral Transmission Model
The route of entry of SARS-CoV-2 is related 
to the binding of viral “spike” protein to a hu-
man cell surface receptor known as angioten-
sin-converting enzyme 2 (ACE2) while another 
cell surface human protein TMPRSS2 assists in 
activation of the coronavirus spike protein and 
facilitate viral cell entry32,33. The major targets of 
SARS-CoV are specific type of cells present in 
lungs, nasal passage and intestines that expressed 
ACE2 and TMPRSS2. Type II pneumocytes cells 
in lungs, absorptive enterocytes in intestines and 
goblet secretory cells in nasal passages serve as 
the main route of viral transmission in human 
body34,35. The levels of ACE2 are high in the 
lungs, therefore, it is considered to play an im-
portant role in the progression of lung disorders 
in relation to COVID-19.
The average incubation period of SARS-CoV-2 
infection is 5.1 days, while 97% of infected pa-
tients develop symptoms within 11.5 days30,36. 
Based on these reports, it is suggested that out 
of 10,000 cases 101 cases will show the sign of 
infection after 14 days of isolation37,38. Thus, 
incubation period is the major key for control of 
SARS-CoV-2 infection. Following contact with 
a confirmed or suspected SARS-CoV-2 case, 14 
days observation are recommended14,39.
Diagnosis of SARS-COV-2
Serological techniques are widely used for di-
agnosis of SARS-CoV-2 infections through esti-
mation of different levels of blood cells33,37,38. The 
variation in the levels of blood cells in SARS-
CoV-2 infected patients are the major indicator of 
the type and severity of the disease14,37. According 
to the study conducted on 99 confirmed patients 
of SARS-CoV-2 infection, the levels of lym-
phocytes, platelets and albumin was decreased 
in contrast with increased levels of neutrophil, 
ALT, AST, D-dimer, bilirubin, creatinine, and 
LDH30,40,41.
Another method of detection of unique viral 
sequences by using amplification technique of 
nucleic acids is reverse Real Time-PCR (rRT-
PCR)42,43. The protocol of Reverse Real Time-
PCR (rRT-PCR) for detection of SARS-CoV-2 
infection is based on alignment and similarity of 
known bat linked coronavirus genome sequence 
and SAR-CoV in addition with five other se-
quences obtained from SARS-CoV-225,44. Current 
diagnostic methods by RT-PCR are based on 
targeting the three viral genes: E gene (encode 
for the envelope protein), RNA-dependent RNA 
polymerase gene (RdRp) and the nucleocapsid 
(N) gene45,46. With the higher sensitivity and 
specificity, recently other assays28,45,47 have been 
developed targeting the separate region of the 
RdRp/Hel gene of SARS-CoV. 
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Potential Therapeutic Approaches 
Against COVID-19 
Till now, scientists are still working to find the 
effective treatment or vaccine to combat against 
the SARS-CoV-2 (COVID-19) as infection rate 
and mortality increases on daily basis. There is 
an essential need of developing an effective strat-
egy and currently available antiviral drugs are 
useful in clinical manifestation improvement48. 
Currently, used antiviral drugs are selected as 
they have been previously found to be an effec-
tive treatment against various viral infections 
for instance SARS, Ebolavirus (EBOV), human 
immunodeficiency virus (HIV), influenza virus 
(InfV) and MERS. These drugs usually act as a 
nucleoside analogues, may be in the form of gua-
nosine or adenine and could target the RNA-de-
pendent RNA polymerase (RDRP)49. Potential 
antiviral drugs, such as remdesivir, corticoste-
roids, tocilizumab chloroquine, hydroxychloro-
quine, interferon, ribavirin, tocilizumab, and sar-
ilumab have been used as a potential agent for the 
treatment50. Remdesivir (RDV), a nucleotide ana-
logue inhibitor of RDRP (RNA-dependent RNA 
polymerase), is known to exert its broad-spec-
trum antiviral activity through inhibition of viral 
replication by premature termination of RNA 
transcription. It has been considered as one of 
the most effective treatment against COVID-19 
infection by reducing the recovery time and 
lowering the mortality rate51. However, unfortu-
nately later in the COVID-19 patients with acute 
respiratory failure and pneumonia, remdesivir 
was not found to be associated statistically sig-
nificant with clinical improvements. Remdesivir 
shows broad antiviral spectrum against HIV, 
hepatitis B virus, MERS-CoV and SARS-CoV, 
both in vivo and in vitro52. In order to clarify the 
effectiveness of the drug, there is a need of puz-
zle to solve related to mode of viral replication, 
immunological pathways and pathogenesis53. Fa-
vipiravir (FPV), a guanine analogue known to 
target RdRP (RNA-dependent RNA polymerase) 
of many RNA viruses, is also considered as a 
potential treatment against COVID-19, it was 
initially approved for influenza viral infections. 
Although its in vitro efficacy on SARS-CoV-2 
is still under investigation, its effectiveness on 
RCTs COVID-19 recruiting patients is now under 
evaluation in combination with interferon-α54. 
Chloroquine and hydroxychloroquine have been 
mainly used in autoimmune diseases (e. g., lupus 
and rheumatoid arthritis) and as an antimalarial 
agent. There is a wide discrepancy from the ex-
isting studies shedding the significance of need 
RCTs in order to access its efficacy as a poten-
tial agent against treatment of COVID-19 infec-
tion55. Passive immunotherapy is the procedure 
to extract neutralizing antibodies from newly 
recovered patients (high titer of antibodies in 
sera present in newly recovered patients) and to 
injected it into infected patient results for deacti-
vating the virus. However, mechanism behind the 
neutralization action of these antibodies is still 
unknown. This mechanism is not only effective 
against SARS-CoV2 infection but also found to 
be a potential treatment from SARS and MERS 
viral infections. Corticosteroids has great poten-
tial because immunosuppressive activity required 
to alter the progression of the pneumonia, and in 
addition it has anti-inflammatory effect. However, 
due to their negative effects on anti-viral immune 
responses the use of corticosteroids against the 
treatment of COVID-19 is controversial. Anoth-
er potential option is Bacillus Calmette-Guérin 
(BCG; weakened strain of Mycobacterium bo-
vis) vaccination which could be effective against 
COVID-19 infection but this method of treatment 
does not recommend by WHO and clinical trials 
are still ongoing to confirm its role as a potential 
agent against SARS-CoV-2 infection56.
Governmental Strategies to 
Tackle the Current Outbreak 
Testing Capacity
So far, the key factor of inconsistency and 
limited availability of COVID-19 testing data 
is due to dependence on publicly available re-
sources. Region wise variation exist in a way 
they report confirmed positive cases. So far 
none of the country testing capacity is more 
than 17% of its total population. Countries 
should only report the number of viral tests 
performed when reporting the testing num-
bers of infection as antibody or serology test 
does not count active viral infections there-
fore do not provide the real picture of num-
ber of active cases of COVID-19 infection. 
The limited testing capacity usually represents a 
smaller number of cases compared to the actual 
cases within that region.
Other factors that affect the testing rate or 
data is availability of testing supplies, test-
ing time or technology used, possibility of 
false negative results due to inappropriate testing 
timing during the course of infection. Among 
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the developing countries, Pakistan with over 220 
million population the testing size remains as low 
as around 14,000 per day57. As shown in Figure 
2, Brazil is at top with 62% of total cases so far 
confirmed from the test. China is among the 
lowest rate in terms of percent of positive cases 
confirmed so far from the test this could be be-
cause the rate of spread of infection in China is so 
fast. Considering the US with highest number of 
cases so far has only 9 percent of cases confirmed 
from the available tests. Data available so far, 
in South Asia the highest number of single day 
20,167 coronavirus test reported on 3rd June 2020 
conducted is in Pakistan. 
Lockdown Restrictions
Lockdowns, curfew, air ban, isolation wards, 
closure of educational institutions, private and 
governmental sector offices, social distance mea-
sures, ban on social gathering, border closure, 
closure of public places, shops, ban on religious 
commemoration & congregational prayer are all 
kinds of possible governmental measures en-
forced partially or completely worldwide to stop 
the spread of infection. Around 3 billion people 
in India were under pandemic lockdowns, the 
biggest lockdowns among all. In various coun-
tries of Europe around 300 million people were 
facing pandemic lockdown. Stringency and en-
forcement of pandemic lockdown varies within 
and among nations58. However, there are some 
Asian countries which enforced strict non phar-
maceutical measures, such as wearing face mask, 
gloves and follows social distancing rules instead 
of strict lockdowns, including South Korea, Ja-
pan, and Indonesia59-61. As reported, after lifting 
the lockdowns restrictions sudden record in num-
ber of cases has been observed in some coun-
tries57,62. Timeline for lockdown implementation 
varies worldwide depending upon rate of spread 
of the infection, testing capacity, public response 
in following of SOPs and the incidence of the 
first reported case as control measures taken by 
government of respective region63.
Since the worldwide incidence of COVID-19 
outbreak, the number of cases has sharply in-
creased however country wise variation persists 
due to several social and biological factors. As il-
lustrated in Figure 3, implementation of lockdown 
reduces the expansion of infections with different 
extend. The pre and post lockdowns effects can 
clearly be seen in the graphs, in incidence of 
number of cases. In the majority of the countries 
flattening of the curve has been observed after 
the implementation of lockdown. In China, the 
epicenter of the initial disease outbreak, after the 
enforcement of lockdown by 23rd Jan 2020, flat-
tening of curve has been observed after almost a 
month from lockdown. According to prediction 
model Figure 3, the effects of post lockdown in 
rate of incidence of COVID-19 infection has been 
more evident in Brazil, India, Chile and Pakistan 
compared to other countries; however, the impact 
has been observed among all countries. 
Lockdowns are not a permanent or long-term 
solution of the current outbreak, instead the lock-
downs should be imposed in regular intervals 
with appropriate SOPs till the availability of vac-
cination or proper medication. Print, electronic 
and social media need to play a positive role to in-
crease public awareness of preventive measures. 
Possible deviation from the expected prediction 
is possible as represented in grey shaded region 
as confidence interval varies among countries. 
In countries such as US, Spain, Italy and Turkey 
at initial time of outbreak before lockdown death 
rate are similar to recovery rate, however, grad-
ual increase in recovery rate has been observed 
compared to rate of death as a result of lockdown 
restrictions as depicted in prediction model Fig-
ure 4. Before lockdown, in Brazil and France the 
death rate is comparatively higher from recovery 
rate but during the lockdown the recovery rate 
gradually increased. 
In countries, such as Russia, India, Germany, 
Iran, Chile, Saudi Arabia, Pakistan, Canada and 
China, a higher rate of recovery is observed as 
compared to the death rate as post lockdown 
Figure 2. Worldwide Testing Scenario in COVID-19 pro-
gression. The percentage of confirmed cases from the total 
number of tests is illustrated in the graph for most infected 
countries. Based on data of 7th June 2020.
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Figure 3. Worldwide impact of lockdown on 
COVID-19 outbreak with predicted scenario. 
Prediction model for worldwide distribution of 
coronavirus outbreak is depicted in graph from 
the first reported date for the most infected 
countries arranged accordingly in descending 
order of total number of cases. The country-
wise trend from the date of first reported 
infection for total number of cases in respect 
to lockdown enforcement varies. Relying 
on magnitude of COVID-19 the length of 
lockdown indicated in black line varies among 
different countries. After lockdown, the total 
number of cases as shown in blue line has 
been under control. The trend of COVID-19 
progression has been predicted till July 
2020. The data are provided by World Health 
Organization (WHO) Coronavirus Disease 
(COVID-19) and Global COVID-19 lockdown 
tracker database till 7th June 2020. 
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Figure 4. Worldwide impact of lockdown 
on death and recovery rate associated with 
COVID-19 outbreak with predicted scenario. 
Prediction model for worldwide distribution 
of death and recovery rate due to coronavirus 
outbreak is depicted in the graph from the first 
reported date for the most infected countries 
arranged accordingly in descending order of 
total number of cases. The country-wise trend 
for total number of deaths and recovery cases 
in respect to lockdown enforcement varies. 
Relying on magnitude of COVID-19 the length 
of lockdown indicated in black line varies 
among different countries. After lockdown, 
total number of observed deaths as shown in 
blue line has been under control. Compared 
to UK, in other countries the rate of recovery 
improved after the lockdown. Prediction based 
on spread of COVID-19 is represented in the 
orange line made till July 2020.
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effect. Despite of the lockdown in UK, the num-
ber of deaths bypasses the number of recovered 
cases. As per prediction model, death rate could 
increase as a result of lifting of lockdown restric-
tions due to hike in number of cases, therefore, 
gradual or partial lifting of lockdown restrictions 
from the least infected region will reflect a better 
strategy along with the following of the proper 
guideline provided by the government.
Worldwide efficient testing strategies along 
with the strict implementation of non-phar-
maceutical interventions could be the best 
and effective strategy against the spread of 
virus. The major constraint to control the infec-
tion as virus and symptoms both are invisible, 
therefore, a sensible approach is the best solution 
against the spread of infection. The other biggest 
challenge faced by the government is to tract and 
distinguish the people who are asymptomatic 
and shows positive as never develop any type 
symptoms for COVID-19 from pre-symptom-
atic carriers those who also test positive 
followed by gradual appearance of the symp-
toms. 
According to the recent studies done across 
six countries in US, China, South Korea, Italy, 
France, and Iran the impact of enforced restric-
tions (event cancellations, travel bans, school 
closings, suspended religious services and stay 
home orders has been accessed). In the US it is 
estimated that if there would be no lockdown, 
there will be about 60 million people infected 
compared to 1.9 million reported so far as a result 
of restrictions. The prominent effect has been 
observed in China and reduces the number of 
infections in 285 million people while currently 
reported cases reached to 84,000 cases so far. 
More or less significant impact has been seen 
which saved around 54 million infections in Iran, 
around 49 million in Italy, 45 million in France 
and 38 million in South Korea. A study64 done in 
Imperial College London stated that the lockdown 
restrictions prevent 3.1 million deaths among 11 
European countries during the lockdown timeline 
from March till May 4. Therefore, sensible exit 
lockdown strategy needs to be enforced to effec-
tively control the spread of the infection.
Conclusions
Pandemics have always been a threat due to 
their deadliest effects on human lives. Our living 
habits may permanently be changed, travelling 
is changing, use of hand sanitizer or gloves may 
be a part of our life, more jobs online as people 
learnt to work from home, social gathering may 
never be a norm in the further years. In some 
countries, cases are declining while in South 
Asia and Africa, Central and South America, 
they are still booming. Countries where cases are 
decreasing can possibly face the sudden surge of 
cases: concern of second peak. The only effective 
control of the existing pandemic is to minimize 
the transmission among carriers especially in 
susceptible population followed by expansion of 
testing capacity, isolation of confirmed cases and 
quarantine. In general, lockdown is not a long-
term solution but enforcing it in regular intervals 
with strict SOPs followed by nation wise policies 
may help. People have to live with coronavirus 
for a long time, let us accept this reality and learn 
to live with it. Herd immunity may be an option, 
but it can raise a second wave. Let’s trust and 
respect the health workers and scientist, working 
for humanity. However, there is an immediate 
need of extensive collaborative research to sum 
up the current research analysis for better allo-
cation and engagement of resources for research 
and development related to COVID-19.
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